Evercore Wealth Management LLC Sells 7,792 Shares of Eli Lilly and Company $LLY

Evercore Wealth Management LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 22.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,054 shares of the company’s stock after selling 7,792 shares during the period. Evercore Wealth Management LLC’s holdings in Eli Lilly and Company were worth $24,883,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in LLY. Eversept Partners LP grew its holdings in shares of Eli Lilly and Company by 78.9% in the first quarter. Eversept Partners LP now owns 19,000 shares of the company’s stock worth $17,476,000 after purchasing an additional 8,377 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Eli Lilly and Company by 3.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,447,173 shares of the company’s stock valued at $1,331,054,000 after buying an additional 46,878 shares during the period. Excelsior Advisor Network LLC boosted its position in Eli Lilly and Company by 112.5% in the 1st quarter. Excelsior Advisor Network LLC now owns 2,320 shares of the company’s stock valued at $2,134,000 after buying an additional 1,228 shares during the period. Quantinno Capital Management LP grew its stake in Eli Lilly and Company by 18.5% in the 1st quarter. Quantinno Capital Management LP now owns 433,880 shares of the company’s stock worth $399,070,000 after acquiring an additional 67,839 shares in the last quarter. Finally, Lazard Asset Management LLC increased its position in shares of Eli Lilly and Company by 7.2% during the first quarter. Lazard Asset Management LLC now owns 718,105 shares of the company’s stock worth $660,491,000 after acquiring an additional 48,183 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LLY has been the subject of a number of research reports. Cantor Fitzgerald boosted their price target on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a report on Monday, July 6th. Barclays lifted their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Guggenheim upped their target price on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Bank of America raised their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Finally, Morgan Stanley lifted their price objective on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Eli Lilly and Company Stock Up 0.2%

Eli Lilly and Company stock opened at $1,197.88 on Tuesday. The business has a fifty day moving average of $1,140.74 and a two-hundred day moving average of $1,041.08. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a market cap of $1.13 trillion, a P/E ratio of 42.55, a P/E/G ratio of 1.48 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% compared to the same quarter last year. During the same period last year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 35.03 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.